[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Leads Biolabs Co.,Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":249},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,65,86,106,125,143,161,184,206,227],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100452396","phase-1-a-phase-iii-clinical-study-of-lbl-024-in-patients-with-advanced-malignant-tumors-100452396",false,"NCT05170958","A Phase I\u002FII Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","A Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n1. Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form;\n2. 18-75 years old (including boundary value), no gender limit in the I\u002FIIa trial phase；18-80 years old (including boundary value), no gender limit in the IIb trial phase；\n3. Subject has adequate organ and bone marrow function，Conforming to laboratory test results:\n4. The expected survival time is at least 12 weeks\n5. ECOG score is 0-1\n6. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. Receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time;\n2. Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment;\n3. medical history of immunodeficiency including positive HIV antibody test;\n4. Women who are pregnant or breastfeeding;\n5. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study","ALL","18 Years","80 Years",{"count":20,"type":21},396,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","To evaluate the phase I\u002FII clinical study of LBL-024 in the treatment of patients with advanced malignant tumors",[28],"Advanced Solid Tumor","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2022-01-06",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Nanjing Leads Biolabs Co.,Ltd","INDUSTRY",49,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100601519","phase-2-a-clinical-trial-of-lbl-024-combination-drug-in-patients-with-advanced-solid-tumourssubstudy-02btchcc-100601519","NCT07111546","A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 02(BTC&HCC)]","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.\n6. There is adequate organ and bone marrow function,Conforms to laboratory test results.\n7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Participation in clinical studies of antineoplastic agents within 4 weeks before the first use of study drug,or Subject is expected to receive any other form of systemic or local anti-tumor therapy outside the protocol during the study.\n2. Use of immunomodulatory drugs within 2 weeks before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.\n3. Patients with active infection and requiring intravenous anti-infective therapy within 2 weeks before the first dose.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Women during pregnancy or lactation.\n7. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism or drug addiction.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.","75 Years",{"count":51,"type":21},140,[25],"An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.",[55],"Advanced Solid Tumour","2026-05-22",{"date":58,"type":33},"2026-05-26",{"date":60,"type":33},"2025-10-20",{"date":62,"type":21},"2027-12-26",{"name":39,"class":40},8,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100618402","phase-2-a-phase-ii-clinical-study-of-lbl-024-combination-therapy-in-patients-with-advanced-solid-tumoursubstudy-03escc-100618402","NCT07331155","A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 03(ESCC)]","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. Age ≥ 18 years at the time of signing the informed consent.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.\n6. There is adequate organ and bone marrow function,Conforms to laboratory test results.\n7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. Participation in clinical studies of antineoplastic agents within 4 weeks before the first use of study drug,or is expected to receive any other form of systemic or local anti-tumor therapy outside the protocol during the study.\n2. Use of immunomodulatory drugs within 2 weeks before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.\n3. Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Active hepatitis B or active hepatitis C.\n7. Women during pregnancy or lactation.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":73,"type":21},110,[25],"An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.",[55],"2026-05-15",{"date":79,"type":33},"2026-05-18",{"date":81,"type":33},"2026-02-26",{"date":83,"type":21},"2028-12-26",{"name":39,"class":40},7,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100600587","phase-1-a-trial-of-lbl-024-monotherapy-lbl-024-combined-with-lbl-007-or-toripalimab-in-patients-with-advanced-melanoma-100600587","NCT07099430","A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma","An Open-label, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy, LBL-024 in Combination With LBL-007 or Toripalimab in Patients With Advanced Melanoma","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours）, the subjects enrolled have at least one measurable neoplasm lesion.\n6. Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.\n\nExclusion Criteria:\n\n1. Subjects who received live vaccination within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose.\n2. Major surgery or other treatment or diagnosis that has a significant impact on the subject within 4 weeks before the first dose.\n3. Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.\n4. History of severe cardiovascular and cerebrovascular disorder.\n5. Active infectious disease.\n6. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.\n7. Women during pregnancy or lactation.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":94,"type":21},200,[24,25],"This study is an open-label, multicenter phase Ib\u002FII study to evaluate the efficacy and safety of LBL-024 monotherapy, LBL-024 in combination with LBL-007 or toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.",[98],"Advanced Melanoma",{"date":79,"type":33},{"date":101,"type":33},"2025-09-05",{"date":103,"type":21},"2027-12-30",{"name":39,"class":40},15,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100596234","phase-1-a-phase-ib-clinical-trial-of-lbl-024-combined-with-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-100596234","NCT07042802","A Phase Ib\u002FⅡ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer","An Open-label, Multicenter Phase Ib\u002FⅡ Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Paclitaxel Injection in Patients With Platinum-resistant Ovarian Cancer","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable lesion.\n6. Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug;Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. The subject is currently participating in any other clinical trial,Or has received or is receiving other investigational agents within 4 weeks prior to the first dose of study drug.\n2. Use of immunomodulatory drugs within 2 weeks prior to the first use of study drug.\n3. Patients with active infection and currently requiring systemic treatment. active pulmonary tuberculosis (TB), receiving anti-tuberculosis treatment or Received anti-tuberculosis treatment within 6 months before screening.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion or ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Active hepatitis B or active hepatitis C.\n7. Women during pregnancy or lactation.\n8. History of mental and\u002For psychiatric illness (impairing understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.\n9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":73,"type":21},[24,25],"This trial is an open-label, multicenter phase Ib\u002FII clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.",[117],"Ovarian Cancer",{"date":79,"type":33},{"date":120,"type":33},"2025-12-02",{"date":122,"type":21},"2028-12-25",{"name":39,"class":40},13,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":53,"conditions":135,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100576311","phase-2-a-clinical-trial-of-lbl-024-combination-drug-in-patients-with-advanced-solid-tumourssubstudy-01nsclc-100576311","NCT06783647","A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 01(NSCLC)]","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.\n6. There is adequate organ and bone marrow function,Conforms to laboratory test results.\n7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. Participation in clinical studies of antineoplastic agents within 4 weeks before the first use of study drug,or Subject is expected to receive any other form of systemic or local anti-tumor therapy outside the protocol during the study.\n2. Use of immunomodulatory drugs within 2 weeks before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.\n3. Patients with active infection.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Active hepatitis B or active hepatitis C.\n7. Women during pregnancy or lactation.\n8. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism or drug addiction.\n9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":133,"type":21},230,[25],[55],{"date":79,"type":33},{"date":138,"type":33},"2025-06-11",{"date":140,"type":21},"2026-12-24",{"name":39,"class":40},24,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":75,"conditions":152,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":85},"100622958","phase-2-a-phase-ii-clinical-trial-of-lbl-024-combination-drug-in-patients-with-advanced-solid-tumoursubstudy-04-100622958","NCT07390383","A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 04]","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. Age ≥ 18 years at the time of signing the informed consent.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.\n6. Patients with histologically confirmed unresectable locally advanced or metastatic gastric\u002Fgastroesophageal junction (G\u002FGEJ) adenocarcinoma.\n7. There is adequate organ and bone marrow function,Conforms to laboratory test results.\n8. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.\n\nExclusion Criteria:\n\n1. Participation in clinical studies of antineoplastic agents within 4 weeks before the first use of study drug,or is expected to receive any other form of systemic anti-tumor therapy outside the protocol during the study.\n2. Use of immunomodulatory drugs within 2 weeks before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.\n3. Patients with active, or who have had and have the possibility of recurrence of autoimmune diseases.\n4. Patients with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.\n5. The patient has a Medical history of immunodeficiency, including HIV antibody positive.\n6. Active hepatitis B or active hepatitis C.\n7. Women during pregnancy or lactation.\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":73,"type":21},[25],[55],"2026-05-12",{"date":155,"type":33},"2026-05-13",{"date":157,"type":33},"2026-04-13",{"date":159,"type":21},"2028-05-30",{"name":39,"class":40},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":5},"100617788","phase-1-a-phase-i-study-to-assess-lbl-047-in-healthy-adults-and-patients-with-systemic-lupus-erythematosus-100617788","NCT07323173","A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus","A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n1. Voluntarily sign and date the informed consent form (ICF) and be willing and able to comply with the scheduled visits, treatment plan, laboratory test, and other study procedures.\n2. Age ≥ 18 and ≤ 60 years at the time of signing the ICF.\n3. Part A:Determined by the investigator to be in good health at the time of signing the ICF.\n4. Part B:Mild to moderate systemic lupus erythematosus: SLEDAI-2K score ≥4 and ≤ 10 at screening.\n5. Females of childbearing potential are willing to use highly effective contraception during the study and for 6 months after administration of the study drug and to avoid egg donation.Women of non-childbearing potential include: those with documented surgical sterilization or documented menopause.\n6. Male of childbearing potential are willing to use highly effective contraception during the study and for 6 months after study drug administration and to avoid sperm donation.Men without fertility potential include those with: A semen sample investigation that confirms azoospermia, definitive evidence of infertility, or a history of vasoligation.For the purpose of this study, men with a \"low sperm count\" (or \"subfertility\") are not considered infertile.\n\nExclusion Criteria:\n\n1. Part A:Symptoms or history of any significant disease, including but not limited to cardiovascular, hepatic, renal or any other disease that may interfere with the study results.\n2. Part A:Abnormalities with clinical significance were indicated by vital signs, physical examination, laboratory test, 12-lead electrocardiogram (ECG), chest X-ray, and abdominal ultrasound.\n3. Part B:History of organ transplant or hematopoietic stem cell\u002Fbone marrow transplant.\n4. Part B:currently receiving treatment for any chronic infection (such as pneumocystosis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteriosis).\n5. Major surgery (as judged by the investigator) within 90 days prior to dosing, or surgery scheduled during the study.\n6. At screening, women of childbearing potential were positive for pregnancy.follicle stimulating hormone (FSH) did not reach postmenopausal level in postmenopausal women (defined as amenorrhoea ≥ 12 months before screening).\n7. Large tattoo, scar or other condition that may interfere with assessment at the injection site.\n8. unable to tolerate venipuncture, difficulty in blood collection or has a history of needle\u002Fblood phobic disorder.\n9. The investigator determines that there are other conditions unsuitable for participation in this study.",true,"60 Years",{"count":171,"type":21},112,[24],"A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus.",[175],"Systemic Lupus Erythematosus","2026-04-09",{"date":178,"type":33},"2026-04-14",{"date":180,"type":33},"2025-12-16",{"date":182,"type":21},"2027-12-16",{"name":39,"class":40},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100528212","phase-1-a-clinical-trial-of-lbl-024-combined-with-etoposide-and-platinum-in-patients-with-advanced-neuroendocrine-carcinoma-100528212","NCT06157827","A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","An Open-label, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.\n2. aged 18-75 years (including borderline values) at the time of signing the informed consent form\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion.\n6. Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period\n2. Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon\n3. Subjects with an active infection that currently requires intravenous anti-infective therapy.\n4. Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention.\n5. medical history of immunodeficiency including HIV antibody positive.\n6. Pregnant or lactating women.\n7. The investigator believes that the subject has other conditions that may affect compliance or that are not suitable for participating in this study.",{"count":192,"type":21},178,[24,25],"An open-label, multicenter phase Ib\u002FII clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)",[196],"Advanced Neuroendocrine Carcinoma","2026-03-10",{"date":199,"type":33},"2026-03-12",{"date":201,"type":33},"2023-12-08",{"date":203,"type":21},"2027-03-28",{"name":39,"class":40},25,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":85},"100614621","phase-1-a-trial-of-lbl-024-monotherapy-or-combination-drug-in-patients-with-triple-negative-breast-cancer-100614621","NCT07281976","A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","An Open-label, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.\n2. At the time of signing the informed consent form, the age was ≥ 18 years old.\n3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n4. The expected survival time is at least 12 weeks.\n5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable lesion.\n6. Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug; Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.Male patients are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug,and do not donate sperm during this period.\n\nExclusion Criteria:\n\n1. Use of immunomodulatory drugs within 2 weeks prior to first dose of study drug.\n2. Patients who received live vaccination within 4 weeks before the first dose of study drug or who are scheduled to receive live vaccination during the study treatment period and within 4 weeks after the last dose.\n3. Patients with clinically uncontrolled pleural effusion, peritoneal effusion, or pericardial effusion.\n4. Active infection within 2 weeks prior to first dose of study drug.\n5. Active infectious disease.\n6. Women with plans for pregnancy,Or women who are pregnant or breastfeeding.\n7. Active hepatitis B or active hepatitis C.\n8. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction.\n9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.\n\n   \\-",{"count":214,"type":21},220,[24,25],"This trial is an open-label, multicenter phase Ib\u002FII clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).",[218],"Triple Negative Breast Cancer","2026-02-10",{"date":221,"type":33},"2026-02-12",{"date":223,"type":33},"2026-01-27",{"date":225,"type":21},"2027-12-31",{"name":39,"class":40},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100519879","phase-1-a-phase-iii-clinical-trial-of-lbl-034-in-patients-with-relapsed-refractory-multiple-myeloma-100519879","NCT06049290","A Phase I\u002FII Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","A Multicenter, Open-label, Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n1. Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form;\n2. Age ≥ 18 years at the time of signing the informed consent;\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale≤ 1；\n4. Documentation of initial diagnosis of multiple myeloma according to IMWG diagnostic criteria；\n5. Have a life expectancy of at least 12 weeks；\n6. Fertile men and women of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine devices, hormonal contraception, and correct use of condoms) from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug,or require elective surgery during the trial period;\n2. Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin-2, and interferon；\n3. Systemic use of corticosteroids or other immunosuppressants within 14 days prior to the initial use of the investigational drug;The following conditions are excluded: Treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of glucocorticoids for preventive therapy (e.g., to prevent contrast allergy);\n4. Patients with active hepatitis B or C；\n5. Subjects with an active infection that currently requires intravenous anti infective therapy;\n6. The patient has a Medical history of immunodeficiency, including HIV antibody positive;\n7. Women during pregnancy or lactation;\n8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.",{"count":235,"type":21},342,[24,25],"This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I\u002FII clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with Relapsed\u002FRefractory Multiple Myeloma (R\u002FR MM).",[239],"Relapsed\u002FRefractory Multiple Myeloma","2025-12-03",{"date":242,"type":33},"2025-12-04",{"date":244,"type":33},"2023-10-20",{"date":246,"type":21},"2027-05-20",{"name":39,"class":40},26,""]